Introduction {#S0001}
============

The emergence of infectious diseases caused by multi-drug-resistant (MDR) pathogens is a major problem in the community, especially in children.[@CIT0001],[@CIT0002] MDR or extreme drug-resistant (XDR) GNB contributes to global infectious diseases in paediatric patients.[@CIT0003] Recent reports have shown that the rate of resistance in GNB increases periodically worldwide.[@CIT0004] The genomic adaptions: acquisition of resistance determinant by horizontal gene transfer and/or spontaneous mutation in the genome are two major mechanisms that confer resistance against antibiotics in bacteria.[@CIT0005],[@CIT0006] The genomic mutation is responsible for modification in target sequences, overexpression of target, ie, efflux pump and reduced intake of antibiotics, while acquired resistance traits can modify the target post-translationally, inactivate antibiotics by hydrolysis or chemical modification, or may provide alternative metabolic pathways, etc.[@CIT0007] MDR or XDR GNB is more notable in developing countries due to the restricted antibiotics, indiscriminate use of the drugs, poor hygiene, dietary deficiency and poor governing supervision.[@CIT0008],[@CIT0009] However, the antimicrobial resistance problem is still underestimated because of inadequate or ineffective diagnosis in some clinical settings.[@CIT0009],[@CIT0010] Extended spectrum β-lactamases (ESBLs) and carbapenemases are key resistance. These are a group of plasmids-borne, heterogeneous, complex and rapidly evolving enzymes which are capable of hydrolysing penicillin, cephalosporin, aztreonam and monobactams.[@CIT0011],[@CIT0012] According to Bush-Jacoby-Medeiros classification, ESBLs have been classified into three major groups: TEM, SHV and CTX-M, while carbapenemases enzymes encoded by alleles of the *bla*~KPC~ gene depict one of the five substantial carbapenemase families, others being the VIM, IMP and Delhi Metallo-β-lactamase (MβL) (NDM), and the OXA-48-like oxacillinases.[@CIT0013]--[@CIT0015] The β-lactamase production is most commonly seen among GNB including *Escherichia coli* (*E. coli*), *Klebsiella pneumoniae* (*K. pneumoniae*), *Acinetobacter baumannii* (*A. baumannii*) *and Pseudomonas aeruginosa* (*P. aeruginosa*).[@CIT0016] In the past few years, high dissemination of ESBLs and carbapenemases-producing GNB were observed worldwide and alarm to developing countries. Children with MDR bacteraemia are more likely to receive inadequate initial antibiotic therapy and have a higher rate of infectious complications and death.[@CIT0017] These observations suggest a critical need for the promotion of antimicrobial stewardship and reduction in unnecessary antibiotic use and avoid the horizontal gene transfer in the paediatric patients.

Methods {#S0002}
=======

Bacterial Isolation and Identification {#S0002-S2001}
--------------------------------------

A total of 170 non-duplicate clinical isolates (GNB) were collected from 158 patients between October 2018 and May 2019 from Shenzhen Children's Hospital (SCH), China. This hospital is a major children hospital in the southern area of China. A single specimen was isolated from n=146 (85.88%) paediatric patient's samples, while two specimens were isolated from n=12 (7%) patient's samples. Among the 170 GNB, 54.12% (n=92) were from male and 45.88% (n=78) were from female; patients\' age ranges from ≥4 months to 12 years. The criteria used for inclusion of the isolates in the present study are as follows: first, isolates must be the Gram-negative. Second, the pathogens may link with the community or hospital-associated infections. Bacterial isolates belonging to family Enterobacteriaceae including *E. coli, K. pneumoniae, Enterobacter cloacae* (*E. cloacae*), *Proteus vulgaris* (*P. vulgaris*) were isolated on MacConkey Agar (Becton Dickinson, USA), *Salmonella species* were cultivated on deoxycholate citrate agar (Merck, USA), *A. baumannii* cultivated on CHROMA^TM^ *Acinetobacter* agar (Merck, USA), while *Elizabethkingia meningoseptica* (*E. meningoseptica*), *Burkholderia cepacia* (*B. cepacia*) cultivated on blood agar, and *P. aeruginosa* were cultivated on cetrimide agar (Merck, USA). Sets of biochemical tests were performed to identify isolates. The precise phylogenetic identity of all the GNB isolates was further confirmed by 16S rRNA gene sequencing. Bacterial species used in this study were isolated and characterized in biological safety cabinet Class II Type. The origin of the specimens was as follows: urine n=58, sputum n=51, pus n=38, blood n=18, catheter-associated (CA) n=2, and cerebral spinal fluid (CSF) n=3 (S-1).

Phenotypic Detection of ESBLs Production {#S0002-S2002}
----------------------------------------

The combination disc test was done for phenotypic detection of ESBLs production. The test was performed by using a disc of both cefotaxime and ceftazidime, alone and in combination with clavulanic acid. Control strain was selected from the characterized strain collection of our laboratory, while ATCC25922 was used as a negative control strain. The ESBLs production result was analysed according to the Clinical and Laboratory Standards Institute (CLSI) guideline.[@CIT0018]

Phenotypic Detection of CRKP {#S0002-S2003}
----------------------------

Carbapenemase production was confirmed by using a newly developed Carbapenem Inactivation Method (CIM) which was first delineated in the year 2015.[@CIT0019] To carry out CIM, an antibiotic susceptibility-testing disc of 10-μg meropenem (MEM) was incubated for 2 hrs in an aqueous suspension of a *K. pneumoniae*. The disc was removed from the suspension and placed onto a Mueller-Hinton agar (MHA) plate seeded with an ATCC25922 indicator organism; followed by overnight incubation, the zone of inhibition was measured to determine whether the MEM has been hydrolysed (growth of the indicator organism under 14 mm area), or still active (\>14 mm large zone of inhibition around the disk). Control strain was selected from the characterized strain collection of our laboratory.

Antimicrobial Susceptibility Patterns {#S0002-S2004}
-------------------------------------

Antimicrobial susceptibility was performed by VITEK\@2 compact system (Biomerieux-Ref. No.27530/275660) method for 21 antimicrobial agents, namely, amoxicillin, amikacin, aztreonam, ceftazidime, ciprofloxacin, ceftriaxone, colistin, cefuroxime, cefuroxime axetile, cefazolin, ertapenem, cefepime, cefoxitin, imipenem, levofloxacin, nitrofurantoin, ampicillin/sulbactam, trimethoprim/sulfamethoxazole, tigecycline, tobramycin, piperacillin-tazobactam. The results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guideline[@CIT0018] and colistin susceptibility was determined according to EUCAST.

Detection of Antimicrobial Resistance Encoding Genes {#S0002-S2005}
----------------------------------------------------

The standard PCR assay was performed to detect the presence of resistance encoding genes: ESBLs encoding genes (*bla*~TEM~, *bla*~SHV~, *bla*~CTX-M~, *bla*~GES~, *bla*~CARB~, *bla*~PER~, *bla*~VEB~ and *bla*~OXA~) using specific primers previously described ([Table 1](#T0001){ref-type="table"}). In addition, carbapenemase genes (*bla*~KPC~ and *bla*~NDM~) and colistin resistance *mcr-1* genes were determined by PCR assay and sequencing. The specific primers were used as described in our previous study ([Table 1](#T0001){ref-type="table"}).[@CIT0020]--[@CIT0022] The purified PCR products were sequenced commercially (Sangon Biotech-Shanghai, China). DNA Sequences were analysed by NCBI-BLAST program.Table 1List of Primers Used in This StudyResistance GenesPrimers Pair SequencesAmplicon Size (bp)Annealing Temperature (°C)References*mcr-1*ATGATGCAGCATACTTCTGTG162656[@CIT0020]TCAGCGGATGAATGCGGTGbla*~NDM~*TGCGGGGTTTTTAATGCTG78553[@CIT0021]TGGCTCATCACGATCATGCbla*~KPC~*ATGTCACTGTATCGCCGTC88354[@CIT0021]TTACTGCCCGTTAACGCCbla*~TEM~*AGGAAGAGTATGATTCAACA53157[@CIT0021]CTCGTCGTTTGGTATGGCbla*~SHV~*GGTTATGCGTTATATTCGCC86657[@CIT0021]TTAGCTTTGCCAGTGCTCbla*~OXA48~*TTGGTGGCATCGATTATCGG74555[@CIT0021]GAGCACTTCTTTTGTGATGGCbla*~SME~*AACGGCTTCATTTTTGTTTAG83155[@CIT0021]GCTTCCGCAATAGTTTTATCAbla*~CMY~*CTGACAGCCTCTTTCTCCA50456[@CIT0021]GCCAAACAGACCAATGCTbla*~VIM~*GTTAAAAGTTATTAGTAGTTTATTG79960[@CIT0021]CTACTCGGCGACTGAGCbla*~IMP~*ATGAGCAAGTTATCTGTATTC74160[@CIT0021]TTAGTTGCTTGGTTTTGATGGbla*~GES~*ATGCGCTTCATTCACGCAC86457[@CIT0022]CTATTTGTCCGTGCTCAGGbla*~CARB~*AAAGCAGATCTTGTGACCTATTC58856[@CIT0022]TCAGCGCGACTGTGATGTATAAACbla*~PER~*AGTCAGCGGCTTAGATA97856[@CIT0022]CGTATGAAAAGGACAATCbla*~VEB~*GCGGTAATTTAACCAGA96157[@CIT0022]GCCTATGAGCCAGTGTTbla*~CTX-M~*TTTGCGATGTGCAGTACCAGTAA54457[@CIT0022]CGATATCGTTGGTGGTGCCATA

Data Analysis and Statistical Tests {#S0002-S2006}
-----------------------------------

Data were double-entered to Epi Data version 3.1 and transferred to SPSS version 20 and Microsoft Excel software for analysis, and the results were presented as tables, pie-charts and graphs. P-values \< 0.05 were considered as statistically significant.

Results {#S0003}
=======

Bacterial Confirmation {#S0003-S2001}
----------------------

A total of 170 GNB most commonly *E. coli* 40% (n=68), *K. pneumoniae* 17.64% (n=30), *E. cloacae* 14.11% (n=24), *P. aeruginosa* 12.94% (n=22), *A. baumannii* 5.88% (n=10) ([Figure 1](#F0001){ref-type="fig"}).Figure 1Distribution of isolated Gram-negative pathogens from Shenzhen Children's Hospital, China.

Resistance Trends for Commonly used Antibiotics {#S0003-S2002}
-----------------------------------------------

We summarized the overall resistance trends of commonly used antibiotics against all the isolated GNB over the study period ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). Overall, ceftriaxone resistance was observed to be the highest 54.11% (n=92). In addition, It has resistance to trimethoprim/sulfamethoxazole 49.41% (n=84), cefuroxime 48.23% (n=82), ampicillin sulbactam 41.76% (n=71), cefazolin 34.70% (n=59), aztreonam 33.52% (n=57), ciprofloxacin 28.82% (n=49), cefoxitin 22.94% (n=39), amoxicillin 19.41% (n=33), ceftazidime 17.64% (n=30), levofloxacin 15.88% (n=27), nitrofurantoin 14% (n=25), cefepime 12.94% (n=22), tobramycin 10.58% (n=18), tigecycline 9.41% (n=16), piperacillin-tazobactam 8.23% (n=14), imipenem and ertapenem 5.29% (n=9) each, amikacin 2.35% (n=4) colistin 1.76% (n=3) ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). From isolated strains, *E. coli* has having resistance against ceftriaxone about 54% (n=37), followed by *K. pneumoniae* 50% (n=15) and *E. cloacae* 50% (n=12), *Salmonella spp*. 50% (n=4), *P. aeruginosa* 45% (n=10), while *C. freundii* were found sensitive to cephalosporin group of antibiotics. Other side *S. typhimurium* showed highest resistance for cephalosporin about 63% (n=5) followed by *E. cloacae, K. pneumoniae, E. coli* about 58% (n=14), 53% (n=16), and 49% (n=33) respectively, [Table 2](#T0002){ref-type="table"}. Conversely, *E. coli*, K. *pneumoniae*, and *P. aeruginosa* isolates were very low resistance for aminoglycoside group ([Table 2](#T0002){ref-type="table"}).Table 2Resistance Patterns of Gram-Negative Bacteria for Selected Antibiotics and Antibiotics ClassesAntibiotic ClassesName of Antibiotics*E. coli* (n=68)*K. pneumoniae* (n=30)*E. cloacae* (n=24)*P. aeruginosa* (n=22)*A. baumannii* (n=10)*S. typhimurium* (n=8)*S. maltophilia* (n=2)*P. vulgaris*(n=2)*B. cepacian* (n=2)*E. meningoseptica* (n=1)*C. freundii* (n=1)CephalosporinCeftazidime151441010010Ceftriaxone371512102411200Cefuroxime33161481510210Cefuroxime Axetile38131392312210Ertapenem53020000000Cefepime144210100000Cefoxitin1710340100000Cefazolin2415581402100PenicillinAmoxicillin187340000100Ampicillin sulbactam30116135301011Piperacillin-Tazobactam83221000000AminoglycosideAmikacin12100010000Tobramycin86121000000Imipenem32010000000QuinolonesCiprofloxacin2510872100110Levofloxacin164152101100MonobactamAztreonam16101082101100Nitrofuran DerivativeNitrofurantoin135332200011SulphonamidesTrimethoprim/Sulfamethoxazole39129127101011PolymyxinColistin11010000000TetracyclineTigecycline46111110000 Figure 2(**A**) Number of isolates in which resistance is detected for each antibiotic. (**B**) Detection percentages of resistance to each antibiotic.

Resistance Patterns for the Different Isolates {#S0003-S2003}
----------------------------------------------

Our results reflected that resistance diversity of the pathogens was not observed in any distinct trends. Among 170 GNB, 71.64% (n=122) shown that MDR phenotype followed by 12.35% (n=21) isolates was shown XDR phonotype, 7.64% (n=13) SDR and 8.23% (n=14) MDS phenotype. Form a total of 68 *E. coli* isolates, 6 (9%), 8 (12%), 41 (60%) and 13 (19%) were multi-drug sensitive (MDS), single-drug resistance (SDR), MDR, XDR, respectively. The overall prevalence of MDR among all isolates was E. *cloacae* 96% (n=23) followed by K. *pneumoniae* 80% (n=24), *P. aeruginosa* 77% (n=17) and *A. baumannii* 60% (n=6) [Table 3](#T0003){ref-type="table"}. The prevalence of XDR among all the isolates were *A. baumannii* 20% (n=2), K. *pneumoniae* 10% (n=3), *P. aeruginosa* 9% (n=2). The based on the combination disc test result, 61.76% (n=105) ESBLs producers were identified and carbapenem inactivation method test result confirms that 17% (n=30) were carbapenemase producer. A significant association was observed between ESBLs producers and carbapenemase producer (*P-*value is 0.003642). No significant association was observed between resistance classes (MDS, SDR, MDR, XDR) and isolated GNB isolates (*P* value is 0.83077).Table 3Distribution of MDS, SDR, MDR, and XDR Pattern of Gram-Negative BacteriaIsolated StrainsTotalMDSSDRMDRXDR*C. freundii*10100*E. meningoseptica*10010*B. cepacia*20020*P. vulgaris*20020*S. maltophilia*20020*S. typhimurium*82141*A. baumannii*102062*P. aeruginosa*2212172*E. cloacae*2401230*K. pneumoniae*3030243*E. coli*68684113Total170141312221[^1]

Genomics of Resistant Isolates {#S0003-S2004}
------------------------------

We explored genome to characterise resistance genes from the GNB. Screening resistance genes showed that Gram-negative isolates harboured *bla*~CTX-M~ 59.41% (n=101) with most common being *bla*~CTX-M-15~ (n=44), *bla*~CTX-M-65~ (n=20), *bla*~CTX-M-90~ (n-12), *bla*~CTX-M-14~ (n=11), *bla*~CTX-M-3~ (n=6), *bla*~CTX-M-27~ (n=4), *bla*~CTX-M-98~, *bla*~CTX-M-211~ and *bla*~CTX-M-64~ (n=1each) (S-2). Additionally, other β-lactamase encoding genes were detected, *bla*~TEM~ 41.11% (n=70), *bla*~SHV~ 34.70% (n=59), *bla*~KPC~ 34.11% (n=58), *bla*~OXA-48~ 18.82% (n=32), *bla*~NDM-1~ 17.64% (n=30), *bla*~GES~ 14.11% (n=24), *bla*~VIM~ 9.41% (n=16), *bla*~CARB~ 8.23% (n=14) most recently discovered plasmid-borne colistin resistance *mcr-1* 1.76% (n=3) [Table 4](#T0004){ref-type="table"}. The *bla*~PER~, *bla*~VEB~ and *bla*~SME~ genes were not detected. The significant co-associations were observed between bla*~CTX-M~* to bla*~TNDM-1~*, bla*~KPC~*, and bla*~TEM~* (p = 0.003462, 0.00001 and 0.000335, respectively)﻿.Table 4Prevalence of Drug Resistance Determinant (Genes) in Isolated Gram-Negative BacteriaDrug Resistance Determinant*E. coli* (n=68)*K. pneumoniae* (n=30)*E. cloacae* (n=24)*P. aeruginosa* (n=22)*A. baumanni﻿* (n=10)*S. typhimurium* (n=8)*S. maltophilia* (n=2)*P. vulgaris* (n=2)*B. cepacian* (n=2)*E. meningoseptica* (n=1)*C. freundii* (n=1)Total n=170*mcr-1*200001000003bla~CTX-M~371918146320110101bla~NDM-1~15651200000130bla*~KPC~*21121280111010158bla*~TEM~*301697330011070bla*~SHV~*1616127330011059bla*~GES~*11315220000024bla*~CARB~*5222011010014bla*~PER~*000000000000bla*~VEB~*000000000000bla*~OXA48~*14470121111032bla*~SME~*000000000000bla~VIM~4622110000016

Discussion {#S0004}
==========

Infection caused by GNB is one of the major burdens on low and middle-income countries because of acquisition of resistance genotype. GNB, more precisely, *E. coli, K. pneumoniae, E. cloacae, P. vulgari, Salmonella species*, account for the most severe forms of infections including urinary tract infection (UTI), bacteraemia and pneumonia. The usual therapeutic approaches to treat such conditions are by antibiotics.[@CIT0024],[@CIT0025] Recent findings on antimicrobial resistance revealed that resistances to frontline antimicrobials among GNB are very common and the resistance can spread from multiple sources through a number of pathogenic or commensal microbes by horizontal gene transfer.[@CIT0026] The overall rate of MDR and XDR of the GNB from SCH were found to be 71% and 12.0%, respectively. Furthermore, the observed MDR rate is significantly associated with prolonged hospital stay and the patients, who die due to MDR bacterial species (even if, it is not statistically significant). On the other hand, the observed XDR rate at our hospital indicates that the problem of antimicrobial resistance is increasing at an alarming rate and circulating Gram-negative pathogenic bacteria in SCH are becoming more resistant to available all available antibiotics. Recent reports from Wenzhou, China have indicated that 60.1% MDR gram-negative pathogen infection in the children's hospital is almost similar to our results.[@CIT0027] The occurrence of a high rate of MDR gram-negative pathogenic bacteria would also have huge potential threat and implications for children's care in the hospital and the community at large. As we are living in the Shenzhen (International City) of a very connected world, it is highly likely for these MDR bacteria to be disseminated to other parts of China and globally.

To the best of our knowledge, there is no previous report from Shenzhen on the rate of MDR and XDR gram-negative pathogenic bacteria from paediatric patients and genetic resistance determinant analysis to compare with these results. The antimicrobial susceptibility test data clearly indicate that a high resistance rate of the gram-negative pathogen to the cephalosporin group of antibiotics has raised a serious concern and become a challenge for clinicians. Therefore, we suggest avoiding indiscriminate use of antibiotics in medical practice which will certainly lower the opportunities for the emergence of resistance. Our antimicrobial susceptibility results are comparable to another part of China, Taiwan, and the USA.[@CIT0028],[@CIT0029] The ESBLs detection test confirms 59% (n=101) ESBLs producers, while 17% were carbapenemase producer which is quite higher than our previous study,[@CIT0017] but comparable to studies done in Nigeria, Nepal and India.[@CIT0030],[@CIT0031] Development of AMR is an outcome of complex microbial interactions and resistance may arise by the acquisition of de-novo mutation during clinical antibiotic treatment or commonly by the acquisition of integrative or replicative mobile genetic elements (MGEs) that have evolved over time in microbes in the natural ecosystem. The environmental reservoirs of resistance genes are widely diverse and similar resistance genes may present in distantly related bacterial species, which can co-exist in the same habitat.[@CIT0032],[@CIT0033] It was reported that *K. pneumoniae, V. cholerae, E. coli, P. aeruginosa*, and *Salmonella* were naturally competent and can uptake naked DNA from the environment in suitable conditions.[@CIT0034],[@CIT0035] In this study, we observed that *bla*~CTX-M~ as the most prevalent genotype of ESBLs-producing gram-negative pathogens in SCH, which is composed of *bla*~CTX-M-15~ followed by *bla*~CTX-M-65~, *bla*~CTX-M-90~, *bla*~CTX-M-14~, *bla*~CTX-M-3~, *bla*~CTX-M-27~, *bla*~CTX-M-98~, *bla*~CTX-M-211~ and *bla*~CTX-M-64~ (S-2). This result indicates the diversity of CTX-M genotype of ESBLs-producing gram-negative pathogens spread in Shenzhen, China. Additional, *bla*~TEM~ followed by *bla*~SHV,~ *bla*~OXA-48,~ *bla*~GES,~ *bla*~CARB~ and *bla*~VIM~ genes exists in isolated GNB. Similar results were reported from Japan and Tanzania.[@CIT0036],[@CIT0037] In our study, bla~CTX-M-55~ is not detected normally in pediatric patients, which means children may not be in contact with an animal since this genotype is mostly circulated via animal origin *E. coli* isolates.[@CIT0038] We do not observe *bla*~VEB~, *bla*~PER~ and *bla*~SME~ from same isolates. We observed that *bla*~KPC~ 34% and *bla*~NDM-1~ 17.64% as the most prevalent carbapenemases encoding genes in GNB. In addition, co-existence of ESBLs encoding *bla*~CTX-M~ genes with carbapenemases encoding genes *bla*~KPC~ or *bla*~NDM-1~ raises a concern about the spread of superbugs in the Shenzhen. Several reports mentioned the co-existence of *bla*~CTX-M~ with *bla*~KPC~ or *bla*~NDM-1~ globally.[@CIT0039] We observed three isolates harbouring plasmid-borne colistin resistance *mcr-1*, even highly spreading over tChina.[@CIT0040] The overall study suggested that limited options are available to treat MDR GNB infection in children.

Conclusion {#S0005}
==========

In past few years, a number of studies have been repeated globally on antimicrobial resistance focused on pathogenicity, prevalence, resistance mechanisms (acquisition and dissemination of resistance genes), as well as on drug-susceptibility testing, rapid diagnosis of AMR pathogens and developing a strategy to re-sensitize the resistance variants against existing drugs of public-health importance. Despite the availability of the plethora of information on the fundamental science of resistance biology, the information on the rise of resistant pathogens across the globe is surprisingly scarce. Our data show that the clinical isolates (gram-negative pathogen) are continuously evolving to counterbalance the bactericidal/bacteriostatic effects of clinically important antimicrobial drugs because of acquisition of resistance elements such as *bla*~CTX-M,~ *bla*~KPC~, *bla*~NDM-1~, *bla*~TEM~, *bla*~SHV~, *bla*~OXA-48~, *bla*~GES~, *bla*~VIM~ and *bla*~CARB~. It is a right time to develop strategies for robust surveillance, restriction on improper antibiotic usage and identify the routes that are facilitating the rapid dissemination of antibiotic resistance in pathogenic and non-pathogenic bacterial cells in children's hospitals.
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[^1]: **Notes:** MDS, susceptible to all antibiotic classes; SDR, resistant to single antibiotic class; MDR, resistant to at least one agent in three or more antimicrobial categories; XDR, resistant to at least one agent in all but two or fewer antimicrobial categories (ie, bacterial isolates remain susceptible to only one or two categories). Source: Based on definitions by Magiorakos et al, 2012.[@CIT0023]
